ADCT: ADC Pharma Cash Calculated per Single Share

ADC Pharma - graphic logo of issuer ADCT

ADC Therapeutics revenues are based on the sale of ZYNLONTA for the therapy of B-cell lymphoma. The annual trend of cash per share demonstrates the current metric level of 1.36. Supply security is ensured by strict temperature control during the transport of antibodies. Meanwhile, the product's patent protection is combined with the provision of discounts to government funds to maintain market positions.

ADC Therapeutics (ADCT) - Cash per Share from 07/04/2022 to 11/20/2026

Comprehensive metric breakdowns and analytics for adctherapeutics.com (ADCT)

- cash availability and cash flow indicators:
Comprehensive company analysis:ADC Therapeutics Corp (ADCT)
Flagship merchandise of ADC Therapeutics

The metric is calculated by dividing total cash and cash equivalents by the number of shares outstanding, determining the actual liquid cushion per share to assess financial stability. For ADC Therapeutics (ADCT), this reserve is critical during the development of targeted conjugates in hematology, which is clearly reflected in the price action of the liquid position per share, allowing the company to balance the risks of underinvestment and excessive capital accumulation.